Quest Diagnostics, through its AmeriPath® subsidiary, is redefining pathology’s role in precision medicine. Traditionally focused on morphologic diagnosis, pathologists now integrate molecular data and AI to drive individualized care. Quest’s PrecisionPathway streamlines oncology diagnostics with standardized, actionable testing—including over 500 gene panels—delivered in 14 days. Collaborations with AI leaders like PathAI enhance diagnostic accuracy and speed, while sponsored testing helps accelerate treatment access. Pathologists are becoming central to therapeutic planning, biomarker discovery, and cross-disciplinary collaboration, making them key orchestrators in delivering smarter, patient-centric healthcare.

Join for free to read